Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ElectroCore, Inc.
  6. Summary
    ECOR   US28531P1030

ELECTROCORE, INC.

(ECOR)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
0.9798(c) 1.01(c) 0.995(c) 0.9634(c) 0.943 Last
739 614 803 116 582 112 760 848 506 637 Volume
-1.69% +3.08% -1.49% -3.18% -2.12% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 5,67 M - -
Net income 2021 -18,9 M - -
Net Debt 2021 - - -
P/E ratio 2021 -2,95x
Yield 2021 -
Sales 2022 10,1 M - -
Net income 2022 -18,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -3,55x
Yield 2022 -
Capitalization 67,9 M 67,9 M -
Capi. / Sales 2021 12,0x
Capi. / Sales 2022 6,71x
Nbr of Employees 45
Free-Float 88,0%
More Financials
Company
ElectroCore, Inc. is a commercial-stage medical device company with a non-invasive vagus nerve stimulation (nVNS) therapy. nVNS is a platform for bioelectronic medical therapy that modulates neurotransmitters and immune function through its effects on both the peripheral and central nervous systems. The Company’s lead product, gammaCore Sapphire, is a simple-to-use handheld delivery system intended for multi-year... 
More about the company
Ratings of electroCore, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ELECTROCORE, INC.
10/21ELECTROCORE : to Announce Third Quarter 2021 Financial Results on Thursday, November 4th
GL
10/20ELECTROCORE : Announces Publication Reviewing the Prescribing of gammaCore for the Treatme..
AQ
10/14ELECTROCORE : GammaCore Device Wins Canadian Approval for Treatment of Adolescent Migraine
MT
10/14ELECTROCORE : Announces Regulatory Approval in Canada to Treat Adolescent Migraine
GL
10/14Electrocore Announces Regulatory Approval in Canada to Treat Adolescent Migraine
CI
10/12ELECTROCORE : Provides Business Update and Select Third Quarter 2021 Financial Guidance - ..
PU
10/12ELECTROCORE, INC. : Results of Operations and Financial Condition, Financial Statements an..
AQ
10/12ELECTROCORE : Provides Business Update and Select Third Quarter 2021 Financial Guidance
AQ
10/12ElectroCore, Inc. Provides Preliminary Unaudited Earnings Guidance for the Third Quarte..
CI
10/07ELECTROCORE : Says Motion to Dismiss Securities Class Action Accepted, Amended Complaint F..
MT
10/07ELECTROCORE : Announces Acceptance of Motion to Dismiss in the Federal Court Securities Cl..
AQ
09/30ELECTROCORE : Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
GL
09/30electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
GL
09/29ELECTROCORE : Announces Open Access and Submission of Manuscript from SAVIOR-1 study of No..
GL
09/29ElectroCore, Inc. Announces Open Access and Submission of Manuscript from Savior-1 Stud..
CI
More news
News in other languages on ELECTROCORE, INC.
10/12ElectroCore, Inc. fournit des indications préliminaires non vérifiées sur le bénéfice p..
More news
Analyst Recommendations on ELECTROCORE, INC.
More recommendations
Chart ELECTROCORE, INC.
Duration : Period :
electroCore, Inc. Technical Analysis Chart | ECOR | US28531P1030 | MarketScreener
Technical analysis trends ELECTROCORE, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,96 $
Average target price 3,15 $
Spread / Average Target 227%
EPS Revisions
Managers and Directors
Daniel S. Goldberger Chief Executive Officer & Director
Brian M. Posner Secretary, Chief Financial & Accounting Officer
F. Peter Cuneo Chairman
Peter S. Staats Chief Medical Officer
Basit Qari Vice President-Information & Digital Technology
Sector and Competitors
1st jan.Capi. (M$)
ELECTROCORE, INC.-38.24%68
MASIMO CORPORATION5.25%15 551
GETINGE AB111.71%12 883
NOVOCURE LIMITED-29.50%12 615
PENUMBRA, INC.59.14%10 188
SHOCKWAVE MEDICAL, INC.104.63%7 460